{"id":11,"date":"2026-08-17T12:53:22","date_gmt":"2026-08-17T12:53:22","guid":{"rendered":"https:\/\/peptide-doc.com\/learn\/retatrutide\/"},"modified":"2026-09-02T19:41:50","modified_gmt":"2026-09-02T19:41:50","slug":"retatrutide","status":"publish","type":"learn_article","link":"https:\/\/peptide-doc.com\/de\/learn\/retatrutide\/","title":{"rendered":"Retatrutide"},"content":{"rendered":"
\nMETA-TITLE:<\/strong> [TODO: Retatrutide \u2014 Triple Agonist Research Profile | Brand]
\nMETA-DESC:<\/strong> [TODO: In-depth retatrutide research profile covering GLP-1\/GIP\/glucagon triple agonism, Phase 2 data, dosing, and safety.]\n<\/div>\n

[TODO]<\/span> Hook \u2014 retatrutide as the first GLP-1\/GIP\/glucagon triple receptor agonist, Eli Lilly development, why it is generating significant research interest<\/p>\n

[IMAGE: Molecular structure or 3D render of Retatrutide peptide]<\/div>\n

What is Retatrutide?<\/h2>\n
    \n
  • [TODO]<\/span> Full name \u2014 Retatrutide (LY3437943), investigational triple agonist peptide<\/li>\n
  • [TODO]<\/span> Developer \u2014 Eli Lilly and Company<\/li>\n
  • [TODO]<\/span> Classification \u2014 GLP-1\/GIP\/glucagon receptor tri-agonist<\/li>\n
  • [TODO]<\/span> Molecular format \u2014 single peptide chain, fatty acid acylation for extended half-life<\/li>\n
  • [TODO]<\/span> Current status \u2014 Phase 2 completed, Phase 3 ongoing<\/li>\n<\/ul>\n

    Mechanism of Action<\/h2>\n
    [IMAGE: Diagram showing the three receptor pathways \u2014 GLP-1R (appetite), GIPR (insulin), GCGR (energy expenditure)]<\/div>\n
      \n
    • [TODO]<\/span> GLP-1 receptor \u2014 appetite suppression, gastric emptying delay, insulin secretion<\/li>\n
    • [TODO]<\/span> GIP receptor \u2014 enhanced insulin sensitivity, potential adipose tissue effects<\/li>\n
    • [TODO]<\/span> Glucagon receptor \u2014 hepatic glucose output, energy expenditure increase, lipid metabolism<\/li>\n
    • [TODO]<\/span> Synergy \u2014 triple agonism additive\/synergistic effects vs mono\/dual agonists<\/li>\n
    • [TODO]<\/span> Half-life \u2014 ~6 days, enabling once-weekly administration in studies<\/li>\n<\/ul>\n

      Research Highlights<\/h2>\n
        \n
      • [TODO]<\/span> Phase 2 trial (2023) \u2014 up to 24.2% body weight reduction at 48 weeks (12mg dose)<\/li>\n
      • [TODO]<\/span> Dose-response \u2014 1mg, 4mg, 8mg, 12mg escalation cohorts<\/li>\n
      • [TODO]<\/span> Metabolic markers \u2014 HbA1c, fasting glucose, lipid panel improvements<\/li>\n
      • [TODO]<\/span> Liver fat reduction \u2014 significant hepatic steatosis reduction observed<\/li>\n
      • [TODO]<\/span> Comparison context \u2014 numerically higher weight reduction than semaglutide\/tirzepatide Phase 2 data<\/li>\n<\/ul>\n

        Dosing Protocols (Research Context)<\/h2>\n
          \n
        • [TODO]<\/span> Escalation \u2014 start low (1mg), titrate over weeks to minimize GI side effects<\/li>\n
        • [TODO]<\/span> Maintenance dose range \u2014 4-12mg once weekly (subcutaneous)<\/li>\n
        • [TODO]<\/span> Administration \u2014 subcutaneous injection, abdomen\/thigh<\/li>\n
        • [TODO]<\/span> Storage \u2014 lyophilized form, reconstitution with BAC water, refrigerate<\/li>\n<\/ul>\n

          Safety & Considerations<\/h2>\n
            \n
          • [TODO]<\/span> GI tolerability \u2014 nausea, diarrhea, vomiting (most common, dose-dependent)<\/li>\n
          • [TODO]<\/span> Heart rate \u2014 mild increase observed in some cohorts<\/li>\n
          • [TODO]<\/span> Thyroid \u2014 standard GLP-1 class C-cell concern (rodent thyroid tumors)<\/li>\n
          • [TODO]<\/span> Limited long-term data \u2014 Phase 2 only, awaiting Phase 3<\/li>\n<\/ul>\n

            Frequently Asked Questions<\/h2>\n
            [FAQ: How does retatrutide differ from tirzepatide?]<\/div>\n
            [FAQ: What makes the glucagon receptor component significant?]<\/div>\n
            [FAQ: What is the recommended reconstitution and storage protocol?]<\/div>\n
            [FAQ: When is Phase 3 data expected?]<\/div>\n

            Related Products<\/h2>\n

            [TODO]<\/span> Link to Retatrutide product page + Weight Management category<\/p>\n","protected":false},"excerpt":{"rendered":"

            [META-DESC TODO: Retatrutide research profile \u2014 triple agonist GLP-1\/GIP\/glucagon receptor peptide, mechanism, studies, protocols.]<\/p>\n","protected":false},"featured_media":0,"template":"","learn_category":[2],"class_list":["post-11","learn_article","type-learn_article","status-publish","hentry","learn_category-weight-management"],"_links":{"self":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/11","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article"}],"about":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/types\/learn_article"}],"version-history":[{"count":1,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/11\/revisions"}],"predecessor-version":[{"id":34,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/11\/revisions\/34"}],"wp:attachment":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/media?parent=11"}],"wp:term":[{"taxonomy":"learn_category","embeddable":true,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_category?post=11"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}